U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H16O6.C17H19ClN2S
Molecular Weight 707.2362
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPROMAZINE PAMOATE

SMILES

c1ccc2c(c1)cc(c(c2Cc3c4ccccc4cc(c3O)C(=O)O)O)C(=O)O.CN(C)CCCN1c2ccccc2Sc3ccc(cc31)Cl

InChI

InChIKey=LCKBXWYKBWCAOP-UHFFFAOYSA-N
InChI=1S/C23H16O6.C17H19ClN2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h1-10,24-25H,11H2,(H,26,27)(H,28,29);3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C23H16O6
Molecular Weight 388.3704
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C17H19ClN2S
Molecular Weight 318.8658
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
Curator's Comment:: description was created based on several sources, including http://pubs.acs.org/doi/abs/10.1021/op000018u | https://www.drugs.com/pro/chlorpromazine.html

Chlorpromazine pamoate (also known as chlorpromazine embonate) is a salt of pamoic acid and a chlorpromazine. Pamoate salts are used in pharmaceutical formulations because they show slow dissolution and are useful in formulations where extended duration of action is required. Chlorpromazine is a phenothiazine antipsychotic. It also exerts sedative and antiemetic activity. The precise mechanism whereby the therapeutic effects of chlorpromazine are produced is not known. It has a wide range of activity arising from its depressant actions on the CNS and its alpha-adrenergic blocking and antimuscarinic activities. Chlorpromazine is a dopamine inhibitor; the turnover of dopamine in the brain is also increased. There is some evidence that the antagonism of central dopaminergic function, especially at the D2-dopaminergic receptor, is related to therapeutic effect in psychotic conditions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2056
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
56.0 nM [Ki]
Target ID: CHEMBL217
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
19.0 nM [Kd]
Target ID: CHEMBL231
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
9.0 nM [Kd]
Target ID: CHEMBL2094251
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
2.6 nM [Kd]
Target ID: CHEMBL2095158
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf
750.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HIBERNAL

Approved Use

For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
Primary
HIBERNAL

Approved Use

For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
Primary
HIBERNAL

Approved Use

For the treatment of schizophrenia, control nausea and vomiting, for relief of restlessness and apprehension before surgery, adjunct in the treatment of tetanus, control the manifestations of the manic type of manic-depressive illness.
PubMed

PubMed

TitleDatePubMed
Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.
1973 Feb
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.drugfuture.com/mt/chlorpromazine-hydrochloride.pdf https://www.drugs.com/dosage/chlorpromazine.html
Acute Schizophrenia/Manic States: usual dose for adults is 500 mg/day. Nausea/Vomiting: usual dose for adults is 10 to 25 mg every 4 to 6 hours as needed. Light Sedation: usual dose for adults is 25 to 50 mg 2 to 3 hours before the operation. Chlorpromazine embonate 144 mg is equivalent to about 100 mg of chlorpromazine hydrochloride.
Route of Administration: Oral
In Vitro Use Guide
The inhibition-dissociation constant (Ki) of a number of neuroleptics for D1 receptors of normal human brain tissue was determined. Phenothiazines ranged from 10 nM to 250 nM, and Ki value for chloropromazine was 56 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:07:10 UTC 2021
Edited
by admin
on Sat Jun 26 09:07:10 UTC 2021
Record UNII
85RG9X8ZHE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPROMAZINE PAMOATE
Common Name English
2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH 2-CHLORO-N,N-DIMETHYL-10H-PHENOTHIAZINE-10-PROPANAMINE (1:1)
Common Name English
CHLORPROMAZINE EMBONATE [WHO-DD]
Common Name English
CHLORPROMAZINE EMBONATE [MART.]
Common Name English
CHLORPROMAZINE EMBONATE
MART.   WHO-DD  
Common Name English
Code System Code Type Description
ECHA (EC/EINECS)
261-487-5
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
PUBCHEM
3085150
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
EPA CompTox
58901-20-5
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
CAS
58901-20-5
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
FDA UNII
85RG9X8ZHE
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
EVMPD
SUB01254MIG
Created by admin on Sat Jun 26 09:07:11 UTC 2021 , Edited by admin on Sat Jun 26 09:07:11 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE